The indications for Gadobutrol injection, a generic substitute for Gadavist, include neurovascular and cardiovascular assessments as well as breast malignancy detection with magnetic resonance imaging (MRI).
Fresenius Kabi has launched Gadobutrol Injection, a generic contrast alternative to Gadavist, for use in magnetic resonance imaging (MRI).
A high relaxivity macrocyclic agent, Gadobutrol Injection offers a range of MRI indications including:
• detection and assessment of malignant breast disease in adults;
• diagnosis and evaluation of supra-aortic or renal artery disease in adults and pediatric patients, including term neonates;
• detection of a disrupted blood brain barrier and/or abnormal vascularity in patients of all ages, including term neonates; and
• assessment of myocardial perfusion and late gadolinium enhancement in patients with suspected or known coronary artery disease (CAD).
“Fresenius Kabi is pleased to introduce Gadobutrol Injection as the newest addition to our (United States) radiology portfolio, expanding the range of cost-effective contrast agent options available to hospitals and clinics,” noted John Ducker, the president and CEO of Fresenius Kabi USA.
The company said Gadobutrol Injection is available in single dose vials at 2, 7.5, 10 and 15 mL
(Editor’s note: For related content, see “MRI Study: Half-Dose Gadopiclenol Offers Similar Visualization and Safety as Full-Dose Gadobutrol.”)
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.